| Ytd | 70.07% | |
| 1y | 14.16% |
| Open | Prev Close | 5.00 | Low | High | Mkt Cap | 266.14M | |||
| Vol | 0.00 | Avg Vol | 1.46M | EPS | -0.08 | P/E | -62.50 | Forward P/E | -6.95 |
| Beta | 1.04 | Short Ratio | 14.47 | Inst. Own | 90.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.97 | 200-d Avg | 4.05 | 1yr Est | 6.75 |
TSVT News
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial resul
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
NEW YORK , March 12, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"),
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
NEW YORK , March 11, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law
On Monday, Bristol Myers Squibb & Co BMY agreed to acquire 2seventy bio, Inc. TSVT at $5.00 per shar
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to inv
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer ce
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive m
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma
2seventy bio, Inc. (TSVT) might move higher on growing optimism about its earnings prospects, which
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of i
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf
2seventy bio, Inc. (NASDAQ:TSVT ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Comp
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $0.18 per share versus the Zacks Consens
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51
During the session on Thursday, 461 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
Tuesday's session saw 729 companies set new 52-week lows.